Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PRIMA study: Niraparib maintenance improves PFS in advanced OC

Publish date:: October 8, 2019

Key clinical point: Niraparib improves PFS when given after first-line chemotherapy for advanced OC.

Major finding: PFS was 21.9 vs. 10.4 months in the treatment vs. placebo groups, respectively (HR, 0.43).

Study details: A phase 3 study of 728 patients.

Disclosures: The PRIMA/ENGOT-OV26/GOG-3012 study was sponsored by TESARO. Dr. González-Martin reported relationships with numerous pharmaceutical companies.

Citation:

González-Martin A et al. ESMO 2019: Abstract LBA1.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,